Implus acquired by Trilantic Capital; foot care co. poised for growth
NEW YORK — Trilantic Capital Partners, a global private equity firm, on Tuesday announced that it has partnered with management to acquire Implus, a leader in the footwear, outdoor and fitness accessories markets. Financial terms of the transaction were not disclosed.
Trilantic will partner with CEO Seth Richards and president Todd Vore to provide capital to allow the company to execute on its key growth initiatives. "Trilantic is a partner who will help us expand across business lines and in new markets, both in the [United States] and overseas, where we see tremendous opportunity," Richards said. "Trilantic has proven to be a successful partner in helping the management teams of middle-market businesses grow organically and through acquisitions. We look forward to a successful partnership."
Implus designs, markets and distributes branded consumer accessories, including insoles, shoe care products, socks, sports monitors, seasonal items and fitness products. The company supplies its products to specialty retailers and mass market chains in 70 countries across the United States, Europe and Asia.
"Implus has a strong competitive position with a proven track record of growth through innovation, customer expansion and strategic acquisition," noted Charlie Moore, partner at Trilantic.
ProPhase launches Cold-Eeze oral spray
DOYLESTOWN, Pa. — ProPhase Labs on Tuesday launched the Cold-Eeze oral spray, which is formulated with zinc gluconate to help reduce the severity and duration of the common cold.
"Our Cold-Eeze oral spray is a new opportunity to provide relief to our consumers in a new delivery system," stated Ted Karkus, chairman and CEO of ProPhase. "Our lozenges have always been a leader in the over-the-counter cough-and-cold category, and we saw Cold-Eeze oral spray as the logical next step in offering our consumers variety and alternatives to the traditional lozenge to help them reduce the severity and duration of their colds."
Two sprays offer the same amount of cold remedy (active ingredient zinc gluconate) as one Cold-Eeze lozenge, the company stated.
Available in cherry and mint flavors, each 13.3-mg bottle contains at least 45 doses.
Health Mart unveils new line of private-label products
SAN FRANCISCO — Health Mart on Tuesday officially unveiled its Health Mart brand, a new line of private-label, over-the-counter products that will help place the Health Mart banner in America’s medicine cabinets.
The Health Mart private label will launch with diabetes products to coincide with National Diabetes Month.
“Health Mart pharmacies continue to be recognized by consumers as healthcare leaders; this is most recently exemplified by the franchise ranking highest in overall customer satisfaction among chain drug stores in the J.D. Power National Pharmacy Study,” stated Brian Tyler, president of McKesson U.S. Pharmaceutical. “The Health Mart private label will help our Health Mart pharmacists advance their relationships with customers with an affordable, high-quality line of over-the-counter health products.”
The distinctive Health Mart private-label package design features a white lab coat combined with the iconic mortar and pestle to reinforce the promise of personalized patient care that Health Mart customers receive.
Additional healthcare categories will be added regularly, with smoking-cessation and analgesics products scheduled to launch in January. The Health Mart private label will grow to include products for upper respiratory, baby care, first aid, personal diagnostics, skin care, vitamins, incontinence, eye and ear care, and digestive health categories.
According to Nielsen, private-label products are growing faster than branded products across most over-the-counter categories, with sales increasing 7% over the past year. Items for the Health Mart private label were selected through a careful analysis of the best-performing products as preferred by consumers. The new line provides Health Mart pharmacies the ability to offer high-quality products at retail prices as much as 20% to 40% less than national-brand varieties.